Endometrial cancer is the sixth most common cancer in women worldwide. While the majority of patients present with early stage disease at diagnosis, efficacious therapeutic options for advanced or recurrent disease are scarce. Apart from the combination of Keytruda and Lenvima approved for treatment of certain patient subpopulations, endometrial cancer is predominantly treated with generic chemotherapy. Lack of efficacious treatment options across numerous treatment settings presents enormous market opportunity for drug developers to address with development of targeted therapeutics.
Markets covered: United States, France, Germany, United Kingdom, and Japan.
Primary research: 3 KOL interviews in the United States, 1 each in France, Germany, United Kingdom and Japan.
Key companies covered: Merck & Co., Eisai, AstraZeneca,GlaxoSmithKline, Roche, Karyopharm Therapeutics and others.
Key drugs covered: Keytruda, Imfinzi, Tecentriq, dostarlimab, Lenvima, Xpovio, Lyparza and others.
Product description: Executive Insights provides indication-specific market intelligence with world class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.